ACUTE LIVER FAILURE: DIAGNOSTIC AND PROGNOSTIC PROBLEMS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Acute liver failure (ALF) is a highly specific and rare syndrome associated with the development of coagulopathy and hepatic encephalopathy, characterized by a sharp deterioration in the biochemical parameters of liver function in persons without previous liver disease. Epidemiological data are rather scarce, and the prognisis is often unfavorable. This article analyzes various classifications and main clinical forms of ALF; the approaches to therapy are described depending on organ-specific complications. Along with the traditional methods of diagnosis, the 13C-methacetin respiratory test (13C-MDT) is considered as an additional method of clinical assessment and outcome prediction in ALF patients.

Full Text

Restricted Access

About the authors

I. G Bakulin

North-Western State Medical University n.a. I.I. Mechnikov

M. P Abatsieva

North-Western State Medical University n.a. I.I. Mechnikov

L. N Belousova

North-Western State Medical University n.a. I.I. Mechnikov

Email: liya-belousova@yandex.ru

Yu. V Medvedev

North-Western State Medical University n.a. I.I. Mechnikov

E. G Nemtsov

North-Western State Medical University n.a. I.I. Mechnikov

References

  1. Germani G., Theocharidou E., Adam R., et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol. 2012;57:288-96. doi: 10.1016/j.jhep.2012.03.017.
  2. Bernal W., Auzinger G., Dhawan A., Wendon J. Acute liver failure. Lancet. 2010;376:190-201.
  3. Craig D.G., Bates C.M., Davidson J.S., et al. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol. 2012;73:285-94. doi: 10.1111/j.1365-2125.2011.04067.x.
  4. Katoonizadeh A., Laleman W., Verslype C., et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010;59:1561-69. doi: 10.1136/gut.2009.189639.
  5. Маевская М.В., Бакулин И.Г, Чирков А.А., и др. Злоупотребление алкоголем среди пациентов гастроэнтерологического профиля. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):24-35.
  6. LiverTox.nih.gov (дата обращения 10.07.2018).
  7. Chalasani I. N., Bonkovsky H.L., Fontana R., et al. Features and Outcomes of 899 Patients with Drug-induced Liver Injury: The DILIN Prospective Study Gastroenterology. 2015;148(7):1340-52.e7. doi: 10.1053/j.gastro.2015.03.006.
  8. Fontana R.J., Seeff L.B., Andrade R.J. et al. Standardization of nomenclature and causality assessment in druginduced liver injury: summary of a Clinical Research Workshop. Hepatol. 2010;52(2):730-42. doi: 10.1002/hep.23696.
  9. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-21.
  10. Trey C., Davidson C.S. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282-398.
  11. Bernuau J., Rueff B., Benhamou J.P Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986;6:97-106.
  12. Gimson A.E., O'Grady J., Ede R.J., et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology. 1986;6:288-94.
  13. O'Grady J.G., Schalm S.W., Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-75.
  14. Tandon B.N., Bernauau J., O'Grady J., et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol. 1999;14:403-4.
  15. Polson J., Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179-97.
  16. Sugawara K., Nakayama N., Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol 2012;47:849-61. doi: 10.1007/s00535-012-0624-x.
  17. Bernal W, Hyyrylainen A., Gera A., et al. Lessons from look-back in acute liver failure? A single centre experience of3300patients. J Hepatol 2013;59:74-80. doi: 10.1016/j.jhep.2013.02.010.
  18. Bernuau J., Benhamou J.P. Classifying acute liver failure. Lancet.1993;342:252-53.
  19. Bernal W., Wendon J. Acute liver failure. New EnglJ Med. 2013;369:2525-34.
  20. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. Journal of Hepatology 2017. 66:1047-81. Doi: 10.1016/j. jhep.2016.12.003.
  21. Lalazar G., Adar T., Ilan Y. Point-of-care continuous (13) C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial. World J Gastroenterol. 2009;15:966-72.
  22. Stravitz R.T., Ilan Y. Yaron Ilan Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? Liver Int. 2017;37(3):328-36. doi: 10.1111/liv.13268
  23. Young P., Bailey M., Beasley R., et al. Effect of a buffered crystalloid solution vs. saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial. JAMA. 2015;314:1701-10. doi: 10.1001/jama.2015.12334.
  24. Russell J.A., Walley K.R., Singer J., et al. Vasopressin vs. norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877-87.
  25. Harvey S.E., Parrott F., Harrison D.A., et al. Trial of the route of early nutritional support in critically ill adults. N Engl J Med. 2014;371:1673-84.
  26. Gordon D., Young L.R., Reddy S., et al. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor. J Hosp Infect 2016;92:173-77. Doi: 10.1016/j. jhin.2015.10.009.
  27. Thiessen S.E., Vanhorebeek I., Derese I., et al. FGF21 Response to Critical Illness: Effect of blood glucose control and relation with cellular stress and survival. J Clin Endocrinol Metab. 2015;100: 1319-27. doi: 10.1210/jc.2015-2700.
  28. O'Riordan A., Brummell Z., Sizer E., et al. Acute kidney injury in patients admitted to a liver intensive therapy unit with paracetamol-induced hepatotoxicity. Nephrol Dial Transplant. 2011;26:3501-508. doi: 10.1093/ndt/ gfr050.
  29. Klinck J., McNeill L., Di Angelantonio E., Menon D.K. Predictors and outcome impact of perioperative serum sodium changes in a high-risk population. Br J Anaesth. 2015;114:615-22. doi: 10.1093/bja/aeu409.
  30. Bagshaw S.M., Bellomo R., Devarajan P., et al. Review article: Renal support in critical illness. Can J Anaesth. 2010;57:999-1013. doi: 10.1007/s12630-010-9376-3.
  31. Slack A.J., Auzinger G., Willars C., et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 2014;34:42-8. Doi: 10.1111/ liv.12221.
  32. Grodzicki M., Kotulski M., Leonowicz D. Results of treatment of acute liver failure patients with use of the prometheus FPSA system, Transplant Proc. 2009;41(8):3079-81. Doi: 10.1016/j. transproceed.2009.08.024.
  33. Karvellas C.J., Fix O.K., Battenhouse H., et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: A retrospective cohort study. Crit Care Med. 2014;42:1157-67. Doi: 10.1097/ CCM.0000000000000144.
  34. Kozek-Langenecker S.A., Afshari A., Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270-382. Doi: 10.1097/ EJA.0b013e32835f4d5b.
  35. Raghavan M., Marik P.E. Therapy of intracranial hypertension in patients with fulminant hepatic failure. Neurocrit Care. 2006;4:179-89.
  36. Bhatia V., Batra Y., Acharya S.K. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure-a controlled clinical trial. J Hepatol. 2004;41:89-96.
  37. Canalese J., Gimson A.E., Davis C., et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut. 1982;23:625-29.
  38. Tofteng F., Larsen F.S. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab. 2004;24:798-804.
  39. Rutherford A., King L.Y., Hynan L.S., et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology. 2012;143:1237-43. doi: 10.1053/j.gastro.2012.07.113.
  40. Sidhu S.S., Sharma B.C., Goyal O., et al. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. J. Hepatology. 2018; 67(2):476.
  41. Бакулин И. Г., Варламичева А.А. Отёчно-асцитический синдром: практический алгоритм. Эффективная фармакотерапия 2014;43:14-20.
  42. Karkhanis J., Verna E.C., Chang M.S., et al. Steroid use in Acute Liver Failure Hepatology. 2014;59(2):612-21. doi: 10.1002/hep.26678 PMID: 23929808.
  43. Antoine D.J., Jenkins R.E., Dear J.W., et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2012;56:1070-79. Doi: 10.1016/j. jhep.2011.12.019.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies